Ocuphire Pharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
OCUP Nasdaq 2834 https://www.ocuphire.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ocuphire Pharma Inc

Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting - Apr 22nd, 2024 12:00 pm
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery - Apr 11th, 2024 2:03 pm
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris - Apr 1st, 2024 11:14 am
Earnings Update: Ocuphire Pharma, Inc. (NASDAQ:OCUP) Just Reported And Analysts Are Trimming Their Forecasts - Mar 13th, 2024 10:41 am
Ocuphire Pharma Full Year 2023 Earnings: Misses Expectations - Mar 10th, 2024 1:47 pm
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update - Mar 8th, 2024 1:00 pm
Ocuphire Pharma to Present in the BIO CEO & Investor Conference - Feb 23rd, 2024 1:00 pm
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 15th, 2024 9:10 pm
Ocuphire Pharma Strengthens Leadership Team with Key Appointments - Feb 14th, 2024 1:00 pm
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference - Feb 5th, 2024 1:00 pm
Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions - Jan 4th, 2024 1:00 pm
Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII - Nov 30th, 2023 1:00 pm
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Nov 27th, 2023 9:38 pm
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer - Nov 27th, 2023 1:00 pm
Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update - Nov 13th, 2023 1:00 pm
Declining Stock and Solid Fundamentals: Is The Market Wrong About Ocuphire Pharma, Inc. (NASDAQ:OCUP)? - Nov 10th, 2023 12:36 pm
Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy - Nov 2nd, 2023 12:00 pm
Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director - Nov 1st, 2023 12:05 pm
Ocuphire Pharma to Present at AAO 2023 and Eyecelerator Retina Showcase - Oct 26th, 2023 12:00 pm
Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October - Oct 6th, 2023 12:00 pm